Next Article in Journal
The Effect of Alternative Splicing Sites on Mirtron Formation and Arm Selection of Precursor microRNAs
Next Article in Special Issue
Activation of G Protein-Coupled Estrogen Receptor 1 (GPER) Attenuates Obesity-Induced Asthma by Switching M1 Macrophages to M2 Macrophages
Previous Article in Journal
Preparation and Epitope Identification of Monoclonal Antibodies against the NS6 Protein of Porcine Deltacoronavirus (PDCoV)
Previous Article in Special Issue
Androgens Modulate Bcl-2 Agonist of Cell Death (BAD) Expression and Function in Breast Cancer Cells
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
IJMS
Volume 25
Issue 14
10.3390/ijms25147646
ijms-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

Leptin Is Associated with Testosterone, Nutritional Markers, and Vascular Muscular Dysfunction in Chronic Kidney Disease

by
Crina Claudia Rusu
1,2,
Ina Kacso
1,2,
Diana Moldovan
1,2,
Alina Potra
1,2,
Dacian Tirinescu
1,2,
Maria Ticala
1,2,
Remus Orasan
3,
Cristian Budurea
3,
Florin Anton
4,
Ana Valea
5,
Cosmina Ioana Bondor
6,* and
Mara Carsote
7,8
1
Department of Nephrology, University of Medicine and Pharmacy “Iuliu Hatieganu” Cluj, 8 Victor Babes, Street, 400012 Cluj-Napoca, Romania
2
Department of Nephrology, County Emergency Clinical Hospital Cluj, 3-5 Clinicilor Street, 400006 Cluj-Napoca, Romania
3
Nefromed Dialysis Center, 40 Ana Aslan Street, 400528 Cluj-Napoca, Romania
4
Department of Cardiology, University of Medicine and Pharmacy “Iuliu Hatieganu” Cluj, 8 Victor Babes, Street, 400012 Cluj-Napoca, Romania
5
Department of Endocrinology, University of Medicine and Pharmacy “Iuliu Hatieganu” Cluj, 8 Victor Babes, Street, 400012 Cluj-Napoca, Romania
6
Department of Medical Informatics and Biostatistics, University of Medicine and Pharmacy “Iuliu Hatieganu” Cluj, 6 Pasteur Street, 400349 Cluj-Napoca, Romania
7
Department of Endocrinology, “Carol Davila” University of Medicine and Pharmacy, Dionisie Lupu Street, Number 37, Sector 1, 020021 Bucharest, Romania
8
Department of Clinical Endocrinology V, “C.I. Parhon” National Institute of Endocrinology, Aviatorilor Ave 34-36, Sector 1, 011863 Bucharest, Romania
*
Author to whom correspondence should be addressed.
Int. J. Mol. Sci. 2024, 25(14), 7646; https://doi.org/10.3390/ijms25147646
Submission received: 11 June 2024 / Revised: 4 July 2024 / Accepted: 10 July 2024 / Published: 12 July 2024
(This article belongs to the Special Issue Hormone Signaling in Human Health and Diseases, 2nd Edition)
Browse Figures
Versions Notes

Abstract

:
Chronic kidney disease (CKD) causes specific hormonal disturbances, such as variations in leptin and testosterone levels and function. These disturbances can promote errors in signaling interaction and cellular information processing and can be implicated in the pathogenesis of atherosclerosis. This study investigates the factors that affect leptin in CKD patients and examines how leptin is related to markers of vascular disease. We conducted a cross-sectional study of 162 patients with CKD in pre-dialysis and dialysis stages. We recorded clinical and laboratory data, including leptin, testosterone, and subclinical atherosclerosis markers like brachial–ankle pulse wave velocity (ba PWV) in pre-dialysis CKD patients and flow-mediated vasodilation (FMD) and nitroglycerin-mediated vasodilation (NMD) in hemodialysis (HD) patients. Leptin was significantly correlated with testosterone in CKD pre-dialysis stages (p < 0.001) and also in HD (p = 0.026), with adipose tissue mass in pre-dialysis stages (p < 0.001), and also in HD (p < 0.001). In women HD patients, leptin correlated with NMD (p = 0.039; r = −0.379); in all HD patients, leptin correlated with C reactive protein (p = 0.007; r = 0.28) and parathormone (p = 0.039; r = −0.220). Our research emphasizes the connection between leptin, adipose tissue, and testosterone in all stages of CKD. Leptin was associated with NMD in HD women and correlated with inflammatory syndrome and parathyroid hormone in all HD patients.

1. Introduction

Chronic kidney disease (CKD) leads to specific metabolic disorders, including hormonal disturbances and persistent inflammatory syndrome. These disorders increase the risk of atherosclerosis and cardiovascular disease to an extremely high level, which exceeds the risk in the general population, worsens the progression of CKD, and leads to high mortality rates. Hormonal disturbances, including modifications in leptin, ghrelin, testosterone, and prolactin levels, are commonly seen in CKD patients. In humans, circulating leptin comes primarily from visceral and subcutaneous adipose tissue [1] but can also be secreted by normal human osteoblasts, subchondral osteoblasts, placental syncytiotrophoblasts, and gastric epithelium [2,3]. In blood, leptin circulates in free and protein-bound forms; biologically active leptin exists in the free form. At the renal level, it is freely filtered glomerular; then, it is captured tubularly and degraded [4,5]. The basic mechanism of tubular reabsorption of leptin is receptor-mediated endocytosis [6]. Thus, it reaches the urinary level in a small amount.
The leptin receptor LepR is found in various tissues, such as adipose tissue, heart, muscle, lung, small intestine, liver, and the central nervous system, especially the hypothalamus [7]. Leptin is a hormone that plays a crucial role in regulating food intake [8]. Through neurohormonal mechanisms, increasing leptin can reduce food intake and improve insulin sensitivity. Leptin also helps in the maturation of the gonads, the regulation of the immune system, and mineral bone metabolism [8]. This hormone intervenes in metabolic regulation in several ways: (1) by significantly reducing appetite, it reduces energy intake [9,10], (2) it increases energy consumption by stimulating the activity of the sympathetic nervous system in the cardiovascular system or by increasing thermogenesis [11,12,13,14,15], (3) it increases lipolysis and the use of lipids as energy fuel [11,13], and (4) it increases glucose turnover and glucose absorption in brown adipose tissue, brain, and heart [16,17].
In addition to all the favorable effects of leptin mentioned above, some studies have indicated that its functions are altered in certain pathological conditions, possibly secondary to errors in intercellular signaling. Leptin can increase oxidative stress, promote endothelial dysfunction, and increase arterial stiffness [18]. As a result of these phenomena, the vulnerability of the atherosclerotic plaque and the risk of thrombosis increase [19]. Statins and antidiabetic drugs (including sitagliptin, liraglutide, and empagliflozin) can modify leptin levels [18]. In addition, leptin can stimulate the activity of the sympathetic nervous system, leading to hypertension [20]. The correlation of leptin with blood pressure values and adipose tissue mass brought into discussion a new possible therapeutic intervention for treating hypertension associated with obesity [21].
Leptin levels are high in CKD patients as an active and free form. However, not all CKD patients have high serum leptin levels, but after adjusting for adipose mass and age, hyperleptinemia was identified in all patients [5]. The high values of leptin in CKD are not solely due to kidney failure; other factors, such as inflammation, reduced erythropoietin levels, hyperinsulinemia, the type of dialysis, dialyzer membrane, and diet, may also be involved [2,22,23].
Hyperleptinemia in CKD has been shown to contribute to insulin resistance, protein-energy wasting, and atherogenic lipid profiles [24,25,26]. In peritoneal dialysis, it was associated with left ventricular hypertrophy [27]. In chronic hemodialysis (HD), low leptin levels have been associated with increased mortality [28] and a higher risk of cardiovascular events [29], and high leptin values were associated with vascular access dysfunction [30]. In patients with end-stage kidney disease, higher leptin values were recorded in those with a history of stroke. Still, among patients with stroke, serum leptin values were lower in those who also had congestive heart failure [18].
Thus, the role of leptin in CKD is not fully understood due to limited research and conflicting data. Therefore, further research is needed to clarify its role in CKD and its impact on cardiovascular disease. The purpose of this study is to evaluate the factors that influence the level of leptin in CKD patients in different stages and to determine the predictor of leptin levels. Additionally, the study aims to investigate the relationship between leptin levels and subclinical markers of atherosclerosis, such as nitroglycerin-mediated vasodilation (NMD), flow-mediated vasodilation (FMD), and pulse wave velocity (PWV) in CKD.

2. Results

The average age of patients in the pre-dialysis stage was 68 years, while in the HD group, it was 61.5 years. Among the patients receiving chronic HD, 56.8% were men, while in the pre-dialysis CKD group, 51.3% were men. Additionally, 19.5% of patients undergoing chronic HD and 37.8% of those with pre-dialytic CKD had diabetes. Table 1 shows the characteristics of the patients and the comparison between groups.
When comparing nutritional markers, leptin, and testosterone levels in men and women in both chronic HD patients and in pre-dialysis patients, we found that higher testosterone levels in men were associated with increased lean tissue mass (LTM), decreased adipose tissue mass (ATM) (only in HD group), and lower leptin levels (see Table 2).

2.1. Hemodialysis Group

The level of leptin in the group treated with HD was directly related to body mass index (BMI), ATM, the inflammatory syndrome indicated by white blood cells (WBCs) and high-sensitive C-reactive protein (hs-CRP), triglycerides, and low-density lipoprotein (LDL) cholesterol. It was inversely related to testosterone levels, intact parathyroid hormone (iPTH), and LTM. The multivariate analysis showed that leptin levels remained significantly associated with ATM, hs-CRP, and testosterone levels (see Table 3).
Figure 1 illustrates the inverse correlation between leptin values and testosterone in the HD group A.
The direct correlation between leptin values and ATM in the HD group A is shown in Figure 2.
Testosterone in HD group A was directly correlated with markers of protein metabolism such as pre-dialysis serum creatinine, serum phosphorus, and LTM but also with hemoglobin and diastolic blood pressure, and inversely with age, LDL cholesterol and total cholesterol, ferritin, and leptin. Multivariate analysis showed that testosterone remained significantly associated with hemoglobin and leptin. Interestingly, in the group of chronic HD men, testosterone correlated only with hemoglobin and NMD (see Table 4).

2.2. Pre-Dialysis Group

The leptin values in the pre-dialysis group correlated directly with BMI, ATM, serum calcium, serum bicarbonate, and eGFR, and inversely with testosterone levels, diastolic blood pressure (DBP), ferritin, and LTM. In the multivariate analysis, the leptin level remained significantly associated with ATM, BMI, LTM, and testosterone levels (see Table 5).
The inverse correlation of leptin values with testosterone in the pre-dialysis group is shown in Figure 3.
Figure 4 shows the direct correlation of leptin values with ATM in the pre-dialysis group.
Testosterone in the pre-dialysis group was directly correlated with markers of protein metabolism, such as LTM, and inversely with leptin and calcium. Multivariate analysis showed that testosterone remained significantly associated with LTM and leptin. Interestingly, in the group of men in the pre-dialysis stages of CKD, testosterone was not associated with any of the monitored parameters (see Table 6).

3. Discussion

According to our study, leptin levels in all patients were significantly influenced by their adipose tissue mass and serum testosterone regardless of the CKD stage. This suggests that the main factor influencing leptin levels in the CKD patients studied is their body fat mass [31,32,33] not renal function. A higher value of adipose tissue mass was linked to higher levels of leptin in the blood, which is consistent with findings from other studies. The association of elevated leptin, an anorexigenic hormone, with high ATM values suggests the possibility of leptin resistance [34]. Adipocytes secrete leptin in CKD due to several mechanisms.
First, adipose tissue can lead to hyperinsulinism, which may increase serum leptin [35]. Second, the fatty acid profile specifically altered in CKD can increase leptin gene expression in subcutaneous adipose tissue and cause hyperleptinemia. The link between fatty acid disorders in CKD and the leptin gene also explains the relationship between leptin and lipids in our dialysis patients. Such correlations have been identified in CKD and the general population [26,36,37,38]. Thirdly, leptin mRNA is high in adipose tissue, which can cause increased serum leptin [39]. It is noted that visceral adipose tissue is particularly associated with hyperleptinemia in CKD [33], but in the general population, it was shown that leptin is mainly produced by subcutaneous white adipose tissue [40]. We mention a positive correlation between waist circumference, a marker of visceral adipose tissue, and leptin in our chronic HD patients.
High leptin levels associated with high adipose tissue mass may favor hypogonadism in the general population and chronic renal failure. This mechanism can explain our study’s inverse correlation between leptin and testosterone [39,41,42,43,44]. In fact, high leptin levels can increase estrogen levels, leading to increased aromatase activity. High aromatase activity can inhibit the hypothalamic–pituitary–gonadal axis and reduce testosterone levels [42]. In addition, in our study, HD women patients with higher ATM levels had higher leptin levels and lower muscle mass than males. The difference in circulating leptin levels between genders is known and may be explained by the higher proportion of adipose tissue and an increased production rate of leptin per unit mass of adipose tissue in women compared to men in the general population [45]. In the case of CKD patients, the findings are conflicting. Some studies show higher levels of leptin in women [46], while in diabetes patients with nephropathy, no gender-based variations in leptin levels were observed [47]. In addition, it was noted that the impact of leptin on weight regulation differs between genders [48]. Testosterone stimulates muscle mass formation by increasing muscle protein production and promoting myoblast differentiation [41]. In our study, muscle tissue mass was a common predictor of testosterone values in the pre-dialysis and dialysis stages. Interestingly, in men with chronic HD, the only marker associated with testosterone was hemoglobin, while in pre-dialysis, none of the analyzed parameters was correlated with serum testosterone. In normal physiology, leptin and testosterone levels may not have an inverse relationship. In situations where there is a mild to moderate leptin deficiency or in states of energy deficit such as fasting, the administration of leptin in a physiological dose can restore the level of androgenic and estrogenic hormones through its effect on the hypothalamic–pituitary–gonadal axis [1,49]. This means that low testosterone levels are associated with low leptin levels. After leptin administration, an increase in testosterone levels was also observed, indicating that the two hormones are directly correlated. These effects highlight the important role of leptin in neuroendocrine regulation in situations where there is a lack of energy and where the gonadal system is suppressed to conserve energy [50] and a lack of normal hormonal signaling in CKD patients.
It is also interesting to note that in our study, the mean testosterone level was found to be higher in the dialytic stage compared to the pre-dialysis stages, with no significant differences in the number of men, especially compared to the patients in stage 3 KDIGO (Kidney Disease Improving Global Outcomes) classification. In other studies, it is emphasized that the number of patients with hypogonadism and low testosterone increases with the progression of CKD [51]. However, several aspects were observed during the analysis of our study patients. First, in stage 3, KDIGO CKD patients were significantly older, and testosterone levels declined with age [52]. Second, stage 3 patients had more abundant ATM and higher serum leptin values, and we discussed the interrelationship between these parameters above.
Testosterone positively affects male cardiovascular health in a concentration-dependent manner in the general population [53], but studies on CKD are limited [54,55]. We found that elevated testosterone levels in male HD patients are associated with low NMD values, a marker of vascular smooth muscle dysfunction, and thus not with cardiovascular protection as in the general population. This association in men, which is somewhat inconsistent with data in the general population, could be related to differences in the cellular response to testosterone in CKD. Vascular endothelial cells contain receptors for androgen hormones, and their activation may vary by sex or other conditions [56].
In addition to the relationship of leptin with adipose tissue and serum testosterone, many other factors and multiple metabolic disorders may condition leptin levels in CKD patients. We observed that serum leptin was related to markers of the inflammatory syndrome and mineral and bone metabolism in the whole group. We recorded associations between leptin, eGFR, and blood glucose in pre-dialysis CKD patients.
In our chronic HD patients, we observed a significant association between leptin levels and hs-CRP as a marker of inflammatory syndrome. We found that patients with high hs-CRP and WBC values also had high leptin values, which is consistent with other studies’ findings [32]. It should be noted that the relationship between inflammatory syndrome and leptin is quite complex and warrants further analysis. On the one hand, studies have shown that in CKD, tumor necrosis factor (TNF) alpha can trigger the production and release of leptin from adipose tissue [57]. Simultaneously, other inflammatory molecules such as hs-CRP, interleukin (IL)-6, and IL-10 can also rise [31]. On the other hand, hyperleptinemia can induce the synthesis of inflammatory mediators and reactive oxygen species [58,59]. As the CKD severity rises, leptin, IL-6, and TNF alpha levels can also rise [60]. Some researchers believe leptin, TNF alpha, and IL-6 are pro-inflammatory cytokines activating the nuclear transcription factor kappa B. This activation can reduce protein synthesis and stimulate the ubiquitin-mediated proteolytic system, causing protein degradation [61]. In addition to the one mediated by testosterone, this mechanism would explain the association of high leptin values with reduced muscle mass in CKD patients.
The leptin levels in our study were directly correlated with factors such as ATM, triglycerides, increased glucose level, and markers of the inflammatory syndrome. These correlations suggest that hyperleptinemia in CKD is associated with an increase in the risk of atherosclerosis. It was mentioned that atherosclerosis is an indirect effect of high leptin levels [62]. Surrogate markers such as NMD, FMD, and PWV are used to detect subclinical atherosclerosis. In our study, we found that chronic HD women with high leptin values had low NMD values, indicating a relationship between hyperleptinemia and vascular smooth muscle dysfunction, which has not been noted in other studies. In the general population, the reduction in ATM was found to lead to a reduction in leptin levels associated with an improvement in endothelial function (increase in FMD) but without any effect on NMD [63]. Experimental data and clinical studies in CKD indicate that leptin in high concentrations can produce endothelial dysfunction by modifying the f-actin cytoskeleton through a mechanism involving the protein kinase B/glycogen synthase kinase β (AKT/GSK3β), nitric oxide, and β-catenin pathway [64,65]. We did not record associations of serum leptin with endothelial dysfunction, but we followed only FMD and not molecules such as vascular cell adhesion protein 1 (V-CAM 1) and intercellular adhesion molecule 1 (I-CAM 1), as in other studies [64].
Apart from these links to atherosclerosis, leptin, a hormone produced by adipose tissue and osteoblasts, plays a crucial role in mineral and bone metabolism. Studies have shown that leptin can stimulate osteoblasts, which are responsible for bone restoration [13], and inhibit osteoclast differentiation [66]. This positive effect on bones is supported by research showing that leptin is associated with reduced bone turnover and improved bone mineral density in patients with end-stage renal disease [67]. In chronic HD patients, leptin levels, serum albumin, and body weight correlate positively with bone mineral density [63,68]. In the same way, our findings in chronic HD patients showed an inverse correlation between leptin and iPTH, which is a hormone that can increase bone turnover and reduce bone mineral density. However, high leptin levels in CKD are not always associated with positive effects on bone. Bone resistance to leptin in CKD has been discussed due to leptin’s two modes of action: a direct stimulatory effect on bone and an opposite indirect effect via the central nervous system [66].
In the dialytic stage, inflammatory syndrome markers and mineral and bone metabolism markers, such as iPTH, significantly correlated with the leptin level. The factors associated with serum leptin in CKD in pre-dialysis stages are similar to those identified in the general population.
Leptin, a glomerular filtered and tubularly metabolized hormone, may increase in CKD patients as eGFR decreases, as shown in other studies [69,70]. In contrast, our research found that leptin levels increased with increasing eGFR and in parallel with increasing ATM. The difference between our study and other results is that we did not adjust leptin levels for age or ATM [70]. Renal function has been observed to only partially influence leptin levels in CKD patients, the main determinant being leptin overproduction in adipose tissue due to hyperinsulinemia and chronic inflammation [35,71]. In turn, leptin can influence kidney function. It can stimulate the synthesis of TGF beta, a molecule with a fibrogenesis role, causing the progression of CKD [72]. Hyperleptinemia may predict a decline in renal function in men over time regardless of the presence of diabetes or hypertension [73].
This study is significant because it highlights the connections of leptin in all phases of CKD and reveals relationships that have not been emphasized in other research. Specifically, it highlights the strong correlation of leptin with ATM and testosterone in pre-dialysis and dialysis patients, the gender variation in leptin in CKD, and the association of leptin with vascular smooth muscle dysfunction as an atherosclerosis marker in women undergoing chronic HD. The multiple connections of leptin in CKD indicate that it intersects with multiple metabolic pathways and pathogenic cascades. Future research will determine whether leptin can be a potential therapeutic target in CKD patients.
Our study has several limitations. First, it included a relatively small number of patients in each stage of CKD, so further studies are needed to confirm the interactions of leptin in this population group. Second, the study was observational by design, so the findings need to be confirmed in a prospective study. Third, there was no control group. Additionally, due to the nature of our cross-sectional data, this study was limited in interpreting causality.

4. Materials and Methods

4.1. Participants

We conducted a cross-sectional observational study involving 162 patients with CKD: 88 patients were in chronic HD treatment in Nefromed Dialysis Center Cluj-Napoca, and 74 patients were in the pre-dialysis stages of CKD in the monitorization of Cluj County Emergency Clinical Hospital Department of Nephrology. All included patients met the inclusion and exclusion criteria and signed informed consent. All procedures in the study followed institutional and national research committee ethical standards and the 1964 Declaration of Helsinki and its subsequent amendments. The Ethics Committee of “Iuliu Hatieganu” University of Medicine and Pharmacy Cluj-Napoca approved the study with IRB number 348/26 September 2017.
The inclusion criteria for pre-dialysis patients were age ≥ 18 years, diagnosis of CKD stage 3–5 pre-dialysis, defined according to the KDIGO [74], and no kidney transplant for at least six months, having stable renal function in the last three months (<5 mL/min/1.73 m2 change in eGFR). The inclusion criteria for HD patients were prevalent HD patients, age > 18 years, and duration of HD at least 6 months (HD vintage). All patients were on a thrice-weekly HD (4–5 h) regimen.
Exclusion criteria for all patients were the following: acute inflammation, severe neoplasia with a life expectancy of <6 months, hepatitis virus infection, and any other serious chronic or acute diseases requiring treatment or absence of data.

4.2. Methods

Demographic data, comorbidities (diabetes, hypertension), and medication at enrollment were obtained from medical records. We also registered clinical data: age, weight, height, systolic blood pressure (SBP), and DBP. Hypertension was diagnosed according to SBP/DBP ≥ 140/90 mmHg, as well as the use of relevant medications. We registered laboratory data (such as urea, creatinine, sodium, potassium, calcium, phosphorus, total cholesterol, LDL-cholesterol, high-density lipoprotein (HDL) cholesterol, blood glucose, iPTH, hs-CRP, hemoglobin, WBC count, calcium, phosphorus, ferritin, albumin, alkaline phosphatase, serum bicarbonate, and serum creatinine in the pre-dialysis stage). Additionally, we have determined the levels of leptin, free testosterone, and prolactin using ELISA, with a minimum detection limit of 0.15 ng/mL for leptin and 0.06 pg./mL for testosterone.
We calculated pulse pressure (PP), PP = SBP − DBP, and BMI based on the formula BMI = weight (kg)/[height (m2)]. Nutrition was also assessed by bioimpedance using the Body Composition Monitor, which is a certified device (manufactured by Fresenius Medical Care, Bad Homburg, Germany) that showed LTM (kg) and ATM (kg) and also calculated lean and fat tissue indexes (LTI and FTI, respectively) [75].
In addition, we measured vascular function in HD patients using markers such as NMD for vascular smooth muscle function and FMD for endothelial function. NMD and FMD were evaluated using high-resolution ultrasound: GE Logiq3 (General Electric Company, Fairfield, CT, USA). In pre-dialysis CKD patients, we evaluated the arterial stiffness expressed by PWV with the Mobil-O-Graph NG device (Medexpert Ltd., Budapest, Hungary).
Our published articles [76,77] described the procedure for measuring NMD, FMD, and PWV.

4.3. Statistical Analysis

The data were presented using the following parameters: qualitative data with absolute and relative frequencies; normally distributed quantitative data with averages and standard deviations; non-normally distributed quantitative data with medians, the 25th, and the 75th percentiles.
Data analysis procedures included conducting an ANOVA test (if normal distribution and variance equality were present) or a Kruskal–Wallis test for the comparison of four means, followed by post-doc analysis, with the use of Scheffe post-doc analysis for ANOVA and the Bonferroni correction for Kruskal–Wallis. A Chi-square test was conducted to compare four frequencies, which was followed by Bonferroni correction. For correlation analysis, the Pearson correlation coefficient was calculated for normally distributed data, and the Spearman correlation coefficient was calculated for non-normally distributed data.
Only significant or almost significant correlations were presented in tables. All the variables significantly or almost significantly correlated with leptin or testosterone were considered as independent variables for multivariate analysis. In multivariate linear analysis, the dependent variables were leptin and testosterone. Only the significant variables in the multivariate models were reported in the tables.
IBM SPSS Statistics for Windows, Version 25.0. IBM Corp., Armonk, NY, USA was used for the analysis. The significance threshold of 0.05 was taken.

5. Conclusions

Our study shows the connection between leptin, adipose tissue, and testosterone in all stages of CKD. We also note that hyperleptinemia in our CKD patients was linked to other proatherogenic factors, such as dyslipidemia and hyperglycemia in all CKD stages and with vascular smooth muscle dysfunction in chronic hemodialyzed women. Additionally, we observe the gender variation in leptin in CKD: in advanced stages of CKD, the inflammatory syndrome impacts leptin values, and leptin is associated with parathormone.

Author Contributions

Conceptualization, C.C.R., M.C. and A.V.; Data curation, C.I.B.; Formal analysis, A.P., M.T., M.C. and C.I.B.; Investigation, F.A. and C.B.; Methodology, C.C.R., D.M., I.K. and C.I.B.; Project administration, C.C.R.; Resources, C.C.R.; Software, D.T., D.M. and C.I.B.; Supervision, C.C.R. and I.K.; Validation, C.C.R., I.K. and F.A.; Visualization, C.C.R., R.O., C.B., A.V., M.T. and M.C.; Writing—original draft, C.C.R.; Writing—review and editing, C.C.R., I.K., M.T., C.I.B. and M.C. All authors have read and agreed to the published version of the manuscript.

Funding

This research received no external funding.

Institutional Review Board Statement

The study was conducted in accordance with the Declaration of Helsinki and approved by the Ethics Committee of “Iuliu Hatieganu” University of Medicine and Pharmacy Cluj-Napoca 348/26 September 2017.

Informed Consent Statement

Informed consent was obtained from all subjects involved in the study.

Data Availability Statement

The research data supporting this study’s findings are not publicly available. Further inquiries can be directed to the corresponding author.

Conflicts of Interest

Author Remus Orasan and Cristian Budurea were employed by the company Nefromed Dialysis Center. The remaining authors declare that the research was conducted in the absence of any commercial or financial relation-ships that could be construed as a potential conflict of interest.

References

  1. Akoumianakis, I.; Antoniades, C. The interplay between adipose tissue and the cardiovascular system: Is fat always bad? Cardiovasc. Res. 2017, 113, 999–1008. [Google Scholar] [CrossRef] [PubMed]
  2. Ghorban-Sabbagh, M.; Nazemian, F.; Naghibi, M.; Shakeri, M.T.; Ahmadi-Simab, S.; Javidi-Dasht-Bayaz, R. Correlation between serum leptin and bone mineral density in hemodialysis patients. J. Renal Inj. Prev. 2016, 5, 112–117. [Google Scholar] [CrossRef] [PubMed]
  3. Zhang, J.; Wang, N. Leptin in chronic kidney disease: A link between hematopoiesis, bone metabolism, and nutrition. Int. Urol. Nephrol. 2014, 46, 1169–1174. [Google Scholar] [CrossRef] [PubMed]
  4. Moorthi, R.N.; Moe, S.M. Recent advances in the noninvasive diagnosis of renal osteodystrophy. Kidney Int. 2013, 84, 886–894. [Google Scholar] [CrossRef] [PubMed]
  5. Merabet, E.; Dagogo-Jack, S.; Coyne, D.W.; Klein, S.; Santiago, J.V.; Hmiel, S.P.; Landt, M. Increased plasma leptin concentration in end-stage renal disease. J. Clin. Endocrinol. Metab. 1997, 82, 847–850. [Google Scholar] [CrossRef] [PubMed]
  6. Verroust, P.J.; Christensen, E.I. Editorial Comments Megalin and cubilin-the story of two multipurpose receptors unfolds. Nephrol. Dial. Transplant. 2002, 17, 1867–1871. [Google Scholar] [CrossRef] [PubMed]
  7. Pérez-Pérez, A.; Toro, A.; Vilariño-García, T.; Maymó, J.; Guadix, P.; Dueñas, J.L.; Fernández-Sánchez, M.; Varone, C.; Sánchez-Margalet, V. Leptin action in normal and pathological pregnancies. J. Cell Mol. Med. 2018, 22, 716–727. [Google Scholar] [CrossRef] [PubMed]
  8. Perakakis, N.; Farr, O.M.; Mantzoros, C.S. Leptin in Leanness and Obesity: JACC State-of-the-Art Review. J. Am. Coll. Cardiol. 2021, 77, 745–760. [Google Scholar] [CrossRef]
  9. Halaas, J.L.; Gajiwala, K.S.; Maffei, M.; Cohen, S.L.; Chait, B.T.; Rabinowitz, D.; Lallone, R.L.; Burley, S.K.; Friedman, J.M. Weight-reducing effects of the plasma protein encoded by the obese gene. Science 1995, 269, 543–546. [Google Scholar] [CrossRef]
  10. Weigle, D.S.; Bukowski, T.R.; Foster, D.C.; Holderman, S.; Kramer, J.M.; Lasser, G.; Lofton-Day, C.E.; Prunkard, D.E.; Raymond, C.; Kuijper, J.L. Recombinant ob protein reduces feeding and body weight in the ob/ob mouse. J. Clin. Investig. 1995, 96, 2065–2070. [Google Scholar] [CrossRef]
  11. Singh, A.; Wirtz, M.; Parker, N.; Hogan, M.; Strahler, J.; Michailidis, G.; Schmidt, S.; Vidal-Puig, A.; Diano, S.; Andrews, P.; et al. Leptin-mediated changes in hepatic mitochondrial metabolism, structure, and protein levels. Proc. Natl. Acad. Sci. USA 2009, 106, 13100–13105. [Google Scholar] [CrossRef] [PubMed]
  12. Vaisse, C.; Halaas, J.L.; Horvath, C.M.; Darnell, J.E., Jr.; Stoffel, M.; Friedman, J.M. Leptin activation of Stat3 in the hypothalamus of wild-type and ob/ob mice but not db/db mice. Nat. Genet. 1996, 14, 95–97. [Google Scholar] [CrossRef]
  13. Hwa, J.J.; Fawzi, A.B.; Graziano, M.P.; Ghibaudi, L.; Williams, P.; Van Heek, M.; Davis, H.; Rudinski, M.; Sybertz, E.; Strader, C.D. Leptin increases energy expenditure and selectively promotes fat metabolism in ob/ob mice. Am. J. Physiol. 1997, 272 Pt 2, R1204–R1209. [Google Scholar] [CrossRef]
  14. Mistry, A.M.; Swick, A.G.; Romsos, D.R. Leptin rapidly lowers food intake and elevates metabolic rates in lean and ob/ob mice. J. Nutr. 1997, 127, 2065–2072. [Google Scholar] [CrossRef]
  15. Commins, S.P.; Watson, P.M.; Padgett, M.A.; Dudley, A.; Argyropoulos, G.; Gettys, T.W. Induction of uncoupling protein expression in brown and white adipose tissue by leptin. Endocrinology 1999, 140, 292–300. [Google Scholar] [CrossRef]
  16. Zeng, W.; Pirzgalska, R.M.; Pereira, M.M.; Kubasova, N.; Barateiro, A.; Seixas, E.; Lu, Y.H.; Kozlova, A.; Voss, H.; Martins, G.G.; et al. Sympathetic neuro-adipose connections mediate leptin-driven lipolysis. Cell 2015, 163, 84–94. [Google Scholar] [CrossRef]
  17. Burcelin, R.; Kamohara, S.; Li, J.; Tannenbaum, G.S.; Charron, M.J.; Friedman, J.M. Acute intravenous leptin infusion increases glucose turnover but not skeletal muscle glucose uptake in ob/ob mice. Diabetes 1999, 48, 1264–1269. [Google Scholar] [CrossRef] [PubMed]
  18. Katsiki, N.; Mikhailidis, D.P.; Banach, M. Leptin, cardiovascular diseases and type 2 diabetes mellitus. Acta Pharmacol. Sin. 2018, 39, 1176–1188. [Google Scholar] [CrossRef]
  19. Beltowski, J. Leptin and atherosclerosis. Atherosclerosis 2006, 189, 47–60. [Google Scholar] [CrossRef] [PubMed]
  20. Simonds, S.E.; Pryor, J.T.; Cowley, M.A. Does leptin cause an increase in blood pressure in animals and humans? Curr. Opin. Nephrol. Hypertens. 2017, 26, 20–25. [Google Scholar] [CrossRef]
  21. Parvanova, A.; Reseghetti, E.; Abbate, M.; Ruggenenti, P. Mechanisms and treatment of obesity-related hypertension-Part 1: Mechanisms. Clin. Kidney J. 2023, 17, sfad282. [Google Scholar] [CrossRef] [PubMed]
  22. Sweigert, P.J.; Bansal, V.K.; Hoppensteadt, D.A.; Saluk, J.L.; Syed, D.A.; Fareed, J. Inflammatory and Metabolic Syndrome Biomarker Analysis of Vascular Outcomes in End-stage Renal Disease. Int. J. Angiol. 2017, 26, 43–48. [Google Scholar] [CrossRef] [PubMed]
  23. Sasso, C.V.; Lhamyani, S.; Hevilla, F.; Padial, M.; Blanca, M.; Barril, G.; Jiménez-Salcedo, T.; Martínez, E.S.; Nogueira, Á.; Lago-Sampedro, A.M.; et al. Modulation of miR-29a and miR-29b Expression and Their Target Genes Related to Inflammation and Renal Fibrosis by an Oral Nutritional Supplement with Probiotics in Malnourished Hemodialysis Patients. Int. J. Mol. Sci. 2024, 25, 1132. [Google Scholar] [CrossRef] [PubMed]
  24. Liu, B.; Qiao, J.; Hu, J.; Fan, M.; Zhao, Y.; Su, H.; Wang, Z.; Yu, Q.; Ma, Q.; Li, Y.; et al. Leptin promotes endothelial dysfunction in chronic kidney disease by modulating the MTA1-mediated WNT/beta-catenin pathway. Mol. Cell Biochem. 2020, 473, 155–166. [Google Scholar] [CrossRef] [PubMed]
  25. Lu, J.W.; Chi, P.J.; Lin, Y.L.; Wang, C.H.; Hsu, B.G. Serum leptin levels are positively associated with aortic stiffness in patients with chronic kidney disease stage 3–5. Adipocyte 2020, 9, 206–211. [Google Scholar] [CrossRef] [PubMed]
  26. Kastarinen, H.; Kesaniemi, Y.A.; Ukkola, O. Leptin and lipid metabolism in chronic kidney failure. Scand. J. Clin. Lab. Investig. 2009, 69, 401–408. [Google Scholar] [CrossRef] [PubMed]
  27. Aguilera, A.; Bajo, M.A.; Rebollo, F.; Diez, J.J.; Diaz, C.; Paiva, A.; Codoceo, R.; Selgas, R. Leptin as a marker of nutrition and cardiovascular risk in peritoneal dialysis patients. Adv. Perit. Dial. 2002, 18, 212–217. [Google Scholar] [PubMed]
  28. Scholze, A.; Rattensperger, D.; Zidek, W.; Tepel, M. Low serum leptin predicts mortality in patients with chronic kidney disease stage 5. Obesity (Silver Spring) 2007, 15, 1617–1622. [Google Scholar] [CrossRef] [PubMed]
  29. Qin, Z.; Yang, Q.; Yang, M.; Han, M.; Xiong, Y.; Liao, R.; Su, B. Serum leptin concentration can predict cardiovascular outcomesand all-cause death in maintenance hemodialysis patients. Clin. Chim. Acta 2021, 520, 87–94. [Google Scholar] [CrossRef]
  30. Yu, T.H.; Tang, W.H.; Hung, W.C.; Lee, T.L.; Tsai, I.T.; Hsuan, C.F.; Chen, C.C.; Chung, F.M.; Lee, Y.J.; Wu, C.C. Elevated plasma leptin levels are associated with vascular access dysfunction in patients on maintenance hemodialysis. J. Clin. Lab. Anal. 2023, 37, e24974. [Google Scholar] [CrossRef]
  31. Considine, R.V.; Sinha, M.K.; Heiman, M.L.; Kriauciunas, A.; Stephens, T.W.; Nyce, M.R.; Ohannesian, J.P.; Marco, C.C.; McKee, L.J.; Bauer, T.L. Serum immunoreactive-leptin concentrations in normal-weight and obese humans. N. Engl. J. Med. 1996, 334, 292–295. [Google Scholar] [CrossRef]
  32. Marshall, J.A.; Grunwald, G.K.; Donahoo, W.T.; Scarbro, S.; Shetterly, S.M. Percent body fat and lean mass explain the gender difference in leptin: Analysis and interpretation of leptin in Hispanic and non-Hispanic white adults. Obes. Res. 2000, 8, 543–552. [Google Scholar] [CrossRef] [PubMed]
  33. Cobo, G.; Cordeiro, A.C.; Amparo, F.C.; Amodeo, C.; Lindholm, B.; Carrero, J.J. Visceral Adipose Tissue and Leptin Hyperproduction Are Associated With Hypogonadism in Men With Chronic Kidney Disease. J. Ren. Nutr. 2017, 27, 243–248. [Google Scholar] [CrossRef]
  34. Vilariño-García, T.; Polonio-González, M.L.; Pérez-Pérez, A.; Ribalta, J.; Arrieta, F.; Aguilar, M.; Obaya, J.C.; Gimeno-Orna, J.A.; Iglesias, P.; Navarro, J.; et al. Role of Leptin in Obesity, Cardiovascular Disease, and Type 2 Diabetes. Int. J. Mol. Sci. 2024, 25, 2338. [Google Scholar] [CrossRef]
  35. Alix, P.M.; Guebre-Egziabher, F.; Soulage, C.O. Leptin as an uremic toxin: Deleterious role of leptin in chronic kidney disease. Biochimie 2014, 105, 12–21. [Google Scholar] [CrossRef] [PubMed]
  36. Noor, S.; Alam, F.; Fatima, S.S.; Khan, M.; Rehman, R. Role of Leptin and dyslipidemia in chronic kidney disease. Pak. J. Pharm. Sci. 2018, 31, 893–897. [Google Scholar]
  37. Nasri, H.; Shirani, S.; Baradaran, A. Lipids in Association with Leptin in Maintenance Hemodialysis Patients. J. Med. Sci. 2006, 6, 173–179. [Google Scholar] [CrossRef]
  38. Ostlund, R.E., Jr.; Yang, J.W.; Klein, S.; Gingerich, R. Relation between plasma leptin concentration and body fat, gender, diet, age, and metabolic covariates. J. Clin. Endocrinol. Metab. 1996, 81, 3909–3913. [Google Scholar] [CrossRef]
  39. Korczyńska, J.; Czumaj, A.; Chmielewski, M.; Śledziński, M.; Mika, A.; Śledziński, T. Increased expression of the leptin gene in adipose tissue of patients with chronic kidney disease–the possible role of an abnormal serum fatty acid profile. Metabolites 2020, 10, 98. [Google Scholar] [CrossRef]
  40. Fain, J.N.; Madan, A.K.; Hiler, M.L.; Cheema, P.; Bahouth, S.W. Comparison of the release of adipokines by adipose tissue, adipose tissue matrix, and adipocytes from visceral and subcutaneous abdominal adipose tissues of obese humans. Endocrinology 2004, 145, 2273–2282. [Google Scholar] [CrossRef]
  41. Rymarz, A.; Matyjek, A.; Gomółka, M.; Niemczyk, S. Lean Tissue Index and Body Cell Mass Can Be Predictors of Low Free Testosterone Levels in Men on Hemodialysis. J. Ren. Nutr. 2019, 29, 529–535. [Google Scholar] [CrossRef]
  42. Khodamoradi, K.; Khosravizadeh, Z.; Seetharam, D.; Mallepalli, S.; Farber, N.; Arora, H. The role of leptin and low testosterone in obesity. Int. J. Impot. Res. 2022, 34, 704–713. [Google Scholar] [CrossRef] [PubMed]
  43. Kapoor, D.; Aldred, H.; Clark, S.; Channer, K.S.; Jones, T.H. Clinical and biochemical assessment of hypogonadism in men with type 2 diabetes: Correlations with bioavailable testosterone and visceral adiposity. Diabetes Care 2007, 30, 911–917. [Google Scholar] [CrossRef]
  44. Gautier, A.; Bonnet, F.; Dubois, S.; Massart, C.; Grosheny, C.; Bachelot, A.; Aubé, C.; Balkau, B.; Ducluzeau, P.H. Associations between visceral adipose tissue, inflammation and sex steroid concentrations in men. Clin. Endocrinol. 2013, 78, 373–378. [Google Scholar] [CrossRef]
  45. Hellström, L.; Wahrenberg, H.; Hruska, K.; Reynisdottir, S.; Arner, P. Mechanisms behind gender differences in circulating leptin levels. J. Intern. Med. 2000, 247, 457–462. [Google Scholar] [CrossRef]
  46. Jiang, Y.; Zhang, J.; Yuan, Y.; Zha, X.; Xing, C.; Shen, C.; Shen, Z.; Qin, C.; Zeng, M.; Yang, G.; et al. Association of Increased Serum Leptin with Ameliorated Anemia and Malnutrition in Stage 5 Chronic Kidney Disease Patients after Parathyroidectomy. Sci. Rep. 2016, 6, 27918. [Google Scholar] [CrossRef]
  47. Chan, W.B.; Ma, R.C.; Chan, N.N.; Ng, M.C.; Lee, Z.S.; Lai, C.W.; Tong, P.C.; So, W.Y.; Chan, J.C. Increased leptin concentrations and lack of gender difference in Type 2 diabetic patients with nephropathy. Diabetes Res. Clin. Pract. 2004, 64, 93–98. [Google Scholar] [CrossRef]
  48. Ramel, A.; Arnarson, A.; Parra, D.; Kiely, M.; Bandarra, N.M.; Martinéz, J.A.; Thorsdottir, I. Gender difference in the prediction of weight loss by leptin among overweight adults. Ann. Nutr. Metab. 2010, 56, 190–197. [Google Scholar] [CrossRef]
  49. Chan, J.L.; Heist, K.; DePaoli, A.M.; Veldhuis, J.D.; Mantzoros, C.S. The role of falling leptin levels in the neuroendocrine and metabolic adaptation to short-term starvation in healthy men. J. Clin. Investig. 2003, 111, 1409–1421. [Google Scholar] [CrossRef] [PubMed]
  50. Chan, J.L.; Mantzoros, C.S. Role of leptin in energy-deprivation states: Normal human physiology and clinical implications for hypothalamic amenorrhoea and anorexia nervosa. Lancet 2005, 366, 74–85. [Google Scholar] [CrossRef]
  51. Skiba, R.; Rymarz, A.; Matyjek, A.; Dymus, J.; Woźniak-Kosek, A.; Syryło, T.; Zieliński, H.; Niemczyk, S. Testosterone Replacement Therapy in Chronic Kidney Disease Patients. Nutrients 2022, 14, 3444. [Google Scholar] [CrossRef] [PubMed]
  52. Ketchem, J.M.; Bowman, E.J.; Isales, C.M. Male sex hormones, aging, and inflammation. Biogerontology 2023, 24, 1–25. [Google Scholar] [CrossRef] [PubMed]
  53. Smith, T.; Batur, P. Prescribing testosterone and DHEA: The role of androgens in women. Cleve Clin. J. Med. 2021, 88, 35–43. [Google Scholar] [CrossRef] [PubMed]
  54. Oh, E.S.; Steele, C.N.; You, Z.; Nowak, K.L.; Jovanovich, A.J. Sex hormones and the risk of cardiovascular disease and mortality in male and female patients with chronic kidney disease: A systematic review and meta-analysis. Physiol. Rep. 2022, 10, e15490. [Google Scholar] [CrossRef]
  55. Gulamhusein, N.; Ahmed, S.B.; Holodinsky, J.K.; Buchan, M.; Hernandez-Reyes, A.; Pyakurel, S.; Sola, D.Y.; Pajevic, M.; Dumanski, S.M. The Association Between Testosterone and Vascular Function in Reproductive-Aged Females With Chronic Kidney Disease. CJC Open 2023, 6 Part B, 530–538. [Google Scholar] [CrossRef]
  56. Sieveking, D.P.; Lim, P.; Chow, R.W.; Dunn, L.L.; Bao, S.; McGrath, K.C.; Heather, A.K.; Handelsman, D.J.; Celermajer, D.S.; Ng, M.K. A sex-specific role for androgens in angiogenesis. J. Exp. Med. 2010, 207, 345–352. [Google Scholar] [CrossRef]
  57. Aminzadeh, M.A.; Pahl, M.V.; Barton, C.H.; Doctor, N.S.; Vaziri, N.D. Human uraemic plasma stimulates release of leptin and uptake of tumour necrosis factor- in visceral adipocytes. Nephrol. Dial. Transplant. 2009, 24, 3626–3631. [Google Scholar] [CrossRef]
  58. Dessie, G.; Ayelign, B.; Akalu, Y.; Shibabaw, T.; Molla, M.D. Effect of Leptin on Chronic Inflammatory Disorders: Insights to Therapeutic Target to Prevent Further Cardiovascular Complication. Diabetes Metab. Syndr. Obes. 2021, 14, 3307–3322. [Google Scholar] [CrossRef]
  59. He, W.-H.; Li, B.; Zhu, X.; Zhang, K.-H.; Li, B.-M.; Liu, Z.-J.; Liu, G.-Y.; Wang, J. The role and mechanism of NADPH oxidase in leptin-induced reactive oxygen species production in hepatic stellate cells. Zhonghua Gan Zang Bing Za Zhi 2010, 18, 849–854. [Google Scholar] [CrossRef]
  60. Ambarkar, M.; Pemmaraju, S.V.; Gouroju, S.; Manohar, S.M.; Bitla, A.R.; Yajamanam, N.; Vishnubhotla, S. Adipokines and their Relation to Endothelial Dysfunction in Patients with Chronic Kidney Disease. J. Clin. Diagn. Res. 2016, 10, BC04–BC08. [Google Scholar] [CrossRef]
  61. Mak, R.H.; Cheung, W. Cachexia in chronic kidney disease: Role of inflammation and neuropeptide signaling. Curr. Opin. Nephrol. Hypertens. 2007, 16, 27–31. [Google Scholar] [CrossRef] [PubMed]
  62. Beldhuis, I.E.; Myhre, P.L.; Bristow, M.; Claggett, B.; Damman, K.; Fang, J.C.; Fleg, J.L.; McKinlay, S.; Lewis, E.F.; O’Meara, E.; et al. Spironolactone in Patients With Heart Failure, Preserved Ejection Fraction, and Worsening Renal Function. J. Am. Coll. Cardiol. 2021, 77, 1211–1221. [Google Scholar] [CrossRef] [PubMed]
  63. Gluszewska, A.; Gryglewska, B.; Rewiuk, K.; Zarzycki, B.; Dzieza-Grudnik, A.; Kwater, A.; Major, P.; Budzynski, A.; Gasowski, J.; Grodzicki, T. Arterial structure and function and its short- and long-term changes after bariatric surgery. J. Physiol. Pharmacol. 2019, 70, 909–916. [Google Scholar] [CrossRef]
  64. Ding, N.; Liu, B.; Song, J.; Bao, S.; Zhen, J.; Lv, Z.; Wang, R. Leptin promotes endothelial dysfunction in chronic kidney disease through AKT/GSK3β and β-catenin signals. Biochem. Biophys. Res. Commun. 2016, 480, 544–551. [Google Scholar] [CrossRef]
  65. Jamroz-Wiśniewska, A.; Gertler, A.; Solomon, G.; Wood, M.E.; Whiteman, M.; Beltowski, J. Leptin-induced endothelium-dependent vasorelaxation of peripheral arteries in lean and obese rats: Role of nitric oxide and hydrogen sulfide. PLoS ONE 2014, 9, e86744. [Google Scholar] [CrossRef]
  66. Coen, G. Leptin and bone metabolism. J. Nephrol. 2004, 17, 187–189. [Google Scholar]
  67. Park, S.-H.; Jia, T.; Qureshi, A.R.; Bárány, P.; Heimbürger, O.; Larsson, T.E.; Axelsson, J.; Stenvinkel, P.; Lindholm, B. Determinants and survival implications of low bone mineral density in end-stage renal disease patients. J. Nephrol. 2013, 26, 485–494. [Google Scholar] [CrossRef]
  68. Wang, C.-H.; Lai, Y.-H.; Lin, Y.-L.; Kuo, C.-H.; Syu, R.-J.; Chen, M.-C.; Hsu, B.-G. Increased Serum Leptin Level Predicts Bone Mineral Density in Hemodialysis Patients. Int. J. Endocrinol. 2020, 2020, 8451751. [Google Scholar] [CrossRef]
  69. Coimbra, S.; Rocha, S.; Valente, M.J.; Catarino, C.; Bronze-da-Rocha, E.; Belo, L.; Santos-Silva, A. New Insights into Adiponectin and Leptin Roles in Chronic Kidney Disease. Biomedicines 2022, 10, 2642. [Google Scholar] [CrossRef]
  70. Shih, Y.L.; Shih, C.C.; Chen, S.Y.; Chen, J.Y. Elevated serum leptin levels are associated with lower renal function among middle-aged and elderly adults in Taiwan, a community-based, cross-sectional study. Front. Endocrinol. 2022, 13, 1047731. [Google Scholar] [CrossRef]
  71. Korczynska, J.; Czumaj, A.; Chmielewski, M.; Swierczynski, J.; Sledzinski, T. The Causes and Potential Injurious Effects of Elevated Serum Leptin Levels in Chronic Kidney Disease Patients. Int. J. Mol. Sci. 2021, 22, 4685. [Google Scholar] [CrossRef] [PubMed]
  72. Park, Y.C.; Lee, S.; Kim, Y.S.; Park, J.M.; Han, K.; Lee, H.; Hong, K.W.; Kim, J.K.; Cho, E.S.; Chung, T.H.; et al. Serum leptin level and incidence of CKD: A longitudinal study of adult enrolled in the Korean genome and epidemiology study(KoGES). BMC Nephrol. 2022, 23, 197. [Google Scholar] [CrossRef] [PubMed]
  73. D’Elia, L.; Manfredi, M.; Perna, L.; Iacone, R.; Russo, O.; Strazzullo, P.; Galletti, F. Circulating leptin levels predict the decline in renal function with age in a sample of adult men (The Olivetti Heart Study). Intern. Emerg. Med. 2019, 14, 507–513. [Google Scholar] [CrossRef] [PubMed]
  74. Levin, A.; Stevens, P.E. Summary of KDIGO 2012 CKD Guideline: Behind the scenes, need for guidance, and a framework for moving forward. Kidney Int 2014, 85, 49–61. [Google Scholar] [CrossRef] [PubMed]
  75. Onofriescu, M.; Mardare, N.G.; Segall, L.; Voroneanu, L.; Cuşai, C.; Hogaş, S.; Ardeleanu, S.; Nistor, I.; Prisadă, O.V.; Sascău, R.; et al. Randomized trial of bioelectrical impedance analysis versus clinical criteria for guiding ultrafiltration in hemodialysis patients: Effects on blood pressure, hydration status, and arterial stiffness. Int. Urol. Nephrol. 2012, 44, 583–591. [Google Scholar] [CrossRef] [PubMed]
  76. Rusu, C.C.; Racasan, S.; Kacso, I.M.; Moldovan, D.; Potra, A.; Tirinescu, D.; Budurea, C.; Orasan, R.; Patiu, I.M.; Bondor, C.I.; et al. The metabolic hormone FGF21 is associated with endothelial dysfunction in hemodialysis patients. Int. Urol. Nephrol. 2017, 49, 517–523. [Google Scholar] [CrossRef]
  77. Rusu, C.C.; Kacso, I.; Moldovan, D.; Potra, A.; Tirinescu, D.; Ticala, M.; Rotar, A.M.; Orasan, R.; Budurea, C.; Barar, A.; et al. Triiodothyronine and Protein Malnutrition Could Influence Pulse Wave Velocity in Pre-Dialysis Chronic Kidney Disease Patients. Diagnostics 2023, 13, 2462. [Google Scholar] [CrossRef]
Ijms 25 07646 g001
Figure 1. Variation in testosterone according to leptin in hemodialysis (HD) group A.
Figure 1. Variation in testosterone according to leptin in hemodialysis (HD) group A.
Ijms 25 07646 g001
Ijms 25 07646 g002
Figure 2. Variation in adipose tissue mass (ATM) according to leptin in hemodialysis (HD) group A.
Figure 2. Variation in adipose tissue mass (ATM) according to leptin in hemodialysis (HD) group A.
Ijms 25 07646 g002
Ijms 25 07646 g003
Figure 3. Variation in testosterone according to leptin in pre-dialysis chronic kidney disease (CKD) patients.
Figure 3. Variation in testosterone according to leptin in pre-dialysis chronic kidney disease (CKD) patients.
Ijms 25 07646 g003
Ijms 25 07646 g004
Figure 4. Variation in adipose tissue mass (ATM) according to leptin in pre-dialysis chronic kidney disease (CKD) patients.
Figure 4. Variation in adipose tissue mass (ATM) according to leptin in pre-dialysis chronic kidney disease (CKD) patients.
Ijms 25 07646 g004
Table 1. Comparisons between groups according to estimated glomerular filtration rate (eGFR) and dialysis treatment.
Table 1. Comparisons between groups according to estimated glomerular filtration rate (eGFR) and dialysis treatment.
VariableGroup A Hemodialysis (n = 88)Group B Std. V KDIGO
(n = 23)		Group C Std. IV KDIGO (n = 26)Group D Std. III KDIGO (n = 25)p
Male sex n (%)50 (56.8)12 (52.2)12 (46.2)14 (56)0.803
Age (years)61.5 (54, 71) b,c65 (60, 70)69 (62, 78)70 (65, 75)0.003
WC (cm)98 (84, 108)104 (93.5, 111)96 (90, 106)105 (104, 108)0.094
BMI (kg/m2)27.54 (23.2, 31)27.3 (25.6, 29.9)28.25 (24.85, 29.6)29.1 (27.7, 33.5)0.133
LTM (kg)29.71 (25.2, 37.64)33.9 (29.25, 52.65)39.5 (26.25, 45)35.35 (26.6, 42.45)0.065
ATM (kg)41.75 (26.51, 51.38)35.3 (23.75, 38.75) e35.5 (32.15, 43.7) f46.8 (40.45, 60.65)0.009
SBP (mmHg)142.32 ± 21.29155.76 ± 24.48145.81 ± 23.88144.67 ± 18.210.140
DBP (mmHg)75 (67, 80) a,b,c94 (86, 98)80 (74, 92)82 (80, 98)<0.001
PP (mmHg)68.28 ± 18.7762.18 ± 18.0662.33 ± 20.1658.67 ± 15.410.115
Diabetes n (%)17 (19.5) a,b,c10 (43.5)10 (38.5)8 (32)0.059
Hypertension n (%)62 (70.5) b18 (85.7)24 (100)19 (90.5)0.005
Fasting glucose (mg/dL)93.89 (87.43, 113)99 (91, 129.5)108 (90, 139.5)101 (94, 122)0.180
Triglycerides (mg/dL)134 (95.33, 181.16)131 (99.5, 170.5)148 (116, 188)126 (93, 159.5)0.675
LDL-cholesterol (mg/dL)100.21 ± 36.88120.53 ± 51.74123.35 ± 46.66127.84 ± 38.30.015
Total cholesterol (mg/dL)173.15 ± 40.6173.89 ± 39.16173.96 ± 32.66188.33 ± 35.580.386
HDL-cholesterol (mg/dL)39.61 (30.75, 47.64)41 (32.5, 47.5)35.5 (28, 41)45 (39, 49.5)0.111
Hemoglobin (g/dL)11.5 (10.65, 12.3) c11 (10.3, 11.8) e12.05 (10.3, 13.2)13.4 (12, 14)0.001
Ferritin (ng/mL)567 (333.03, 782.65) a,b,c178.5 (63.5, 351)98 (34, 186)88.5 (61.5, 157)<0.001
Hs-CRP (mg/dL)0.59 (0.23, 1.33)0.5 (0.2, 1.27)0.53 (0.29, 1.19)0.38 (0.23, 0.89)0.660
WBC (no./mmc)6440 (5530, 7815) c7770 (6120, 9800)7315 (6200, 8370)8630 (6500, 8930)0.005
Bicarbonate level (mEq/L)21.4 (18.45, 24.25)19.15 (16.3, 20.85)19.9 (17.3, 23.6)20 (17.7, 22.3)0.068
Calcium (mg/dL)8.9 (8.32, 9.2)8.66 (8.04, 9.1) c9.23 (8.64, 9.68)9.32 (8.94, 9.62)0.003
Phosphorus (mg/dL)4.71 (3.98, 5.89) b,c4.72 (4.18, 5.81) d,e3.7 (3.16, 4.48)3.15 (2.91, 3.53)<0.001
AP (UI/L)73 (55.92, 95.43)86 (70, 98)83 (77.5, 107.5)75 (70, 110.5)0.175
iPTH (pg/mL)286.75 (164.65, 729.65) b,c283.95 (151.85, 398.85) d,e104.1 (52.15, 153.1)104.2 (78.3, 152.45)<0.001
Creatinine (mg/dL)8.59 (7.3, 10.4) a,b,c4.7 (4.04, 6.33) d,e2.4 (2.09, 2.51) f1.56 (1.37, 1.68)<0.001
Albumin (g/dL)3.91 (3.7, 4.08) b,c3.76 (3.56, 4.13) d3.57 (3.47, 3.82) f4.38 (3.9, 4.46)0.002
eGFR (mL/min/m2) 10.17 ± 3.11 d,e23.63 ± 4.3 f41.68 ± 8.13<0.001
Testosterone (ng/mL)2.1 (0.7, 4)2.7 (0.6, 3.55)0.65 (0.4, 3.6)0.9 (0.4, 3.2)0.076
Leptin (ng/mL)5.99 (1.57, 31.14)3.41 (1.9, 9.67) e14.48 (3.86, 37.9)19.98 (6.33, 39.44)0.020
Betablockers n (%)50 (56.8)12 (54.5)13 (52)14 (66.7)0.774
ACEI + ARB37 (42)7 (31.8)14 (56)11 (52.4)0.319
Statin n (%)16 (18.2)8 (42.1)6 (24)7 (33.3)0.111
Antiagregants n (%)32 (36.4)4 (19)10 (40)5 (23.8)0.301
Ba PWV (cm/s)-9.98 ± 2.511.12 ± 2.2510.65 ± 2.110.324
NMD (%)7.25 (2.27, 12.5)----
FMD (%)8.33 (4.31, 14.29)----
a p < 0.05 when comparing group a with group b; b p < 0.05 when comparing group a with group c; c p < 0.05 when comparing group a with group d; d p < 0.05 when comparing group b with group c; e p < 0.05 when comparing group b with group d; f p < 0.05 when comparing group c with group d; significant p value with bold; std.—stadium; n—number of people; no.—number of cells; BMI—body mass index; SBP—systolic blood pressure; DBP—diastolic blood pressure; PP—pulse pressure; eGFR—estimated glomerular filtration rate; LTM—lean tissue mass; ATM—adipose tissue mass; LDL—low-density lipoprotein; HDL—high-density lipoprotein; iPTH—Intact parathyroid hormone; Ba PWV—brachial–ankle pulse wave velocity; ACEI—angiotensin-converting enzyme inhibitors; ARB—angiotensin II receptor blockers; WC—waist circumference; NMD—nitroglycerin-mediated vasodilatation; FMD—flow-mediated vasodilation; hs-CRP—high-sensitive C-reactive protein; AP—alkaline phosphatase; WBC—white blood cell; arithmetic mean ± standard deviation; median (25th–75th percentile).
Table 2. Comparisons between men and women in group A with dialysis treatment and in pre-dialysis group.
Table 2. Comparisons between men and women in group A with dialysis treatment and in pre-dialysis group.
VariableGroup A Hemodialysis (n = 88)Group Pre-Dialysis (n = 74)
Women (n = 38)Men (n = 50)pWomen (n = 36)Men (n = 38)p
Age (years)66 (56, 75)59 (52, 68)0.03270 (65, 77)67 (61, 71)0.122
WC (cm)99 (80, 115)97.5 (85, 104)0.622105 (91, 107)104 (97, 109)0.254
BMI (kg/m2)29.12 (24.38, 36.48)26.54 (22.83, 29.53)0.01029.85 (26.4, 33.3)28.2 (26.75, 29.1)0.168
LTM (kg)25.98 (22.47, 27.96)35.56 (30.12, 43.41)<0.00127.1 (24.7, 34.7)42.4 (36, 52.7)<0.001
ATM (kg)43.44 (30.15, 62.45)39.65 (24.95, 46.62)0.01340.9 (35.1, 55.2)36.6 (30.2, 44.1)0.167
SBP (mmHg)139.26 ± 18.81144.64 ± 22.920.243143 (127, 162)151 (130, 170)0.254
DBP (mmHg)70 (67, 78)80 (70, 82)0.02080.5 (74, 96)91 (81, 99)0.022
PP (mmHg)68.66 ± 19.2368 ± 18.60.87266 (44, 74)57 (50, 72)0.856
Diabetes n (%)6 (15.8)11 (22.4)0.43713 (36.1)15 (39.5)0.766
Hypertension n (%)26 (68.4)36 (72)0.71526 (86.7)35 (97.2)0.169
Fasting glucose (mg/dL)93.5 (87.2, 110)94 (87.65, 115)0.150108.5 (99, 139)97 (89, 124.5)0.896
Triglycerides (mg/dL)145.97 (102, 225)125.69 (94.05, 163.51)0.080148 (114.5, 171.5)126 (93, 155.5)0.541
LDL-cholesterol (mg/dL)106 ± 36.395.81 ± 37.060.201106.8 (76.2, 140)136 (105, 163)0.055
Total cholesterol (mg/dL)184.89 ± 40.36164.22 ± 38.830.017171.5 (153.5, 201)176 (155, 195.5)0.754
HDL-cholesterol (mg/dL)41.25 (30.14, 49)36.5 (31.69, 45.8)0.37442 (32.5, 48.5)39 (33, 46)0.778
Hemoglobin (g/dL)11.05 (10.6, 11.6)12 (10.8, 12.6)0.01511.55 (10.75, 12.5)13 (10.3, 14.8)0.306
Ferritin (ng/mL)665.7 (402.34, 846.6)472 (317.5, 723)0.03391 (55, 186)106 (63, 279.5)0.679
Hs-CRP (mg/dL)0.61 (0.34, 1.43)0.53 (0.21, 1.32)0.4400.43 (0.2, 0.91)0.52 (0.34, 1.42)0.236
WBC (no./mmc)6210 (5530, 7440)6495 (5260, 7880)0.9477065 (6160, 8875)7800 (6410, 9060)0.146
Bicarbonate level (mEq/L)22.8 (18.2, 24.1)20.5 (18.6, 24.5)0.33019 (17.3, 21.1)19.6 (16.5, 22.3)0.673
Calcium (mg/dL)8.97 (8.4, 9.2)8.79 (8.24, 9.2)0.3039.3 (8.93, 9.68)8.79 (8.44, 9.3)0.314
Phosphorus (mg/dL)4.5 (3.8, 5.19)5.12 (4.08, 6.84)0.1274.08 (3.48, 4.88)3.56 (2.93, 4.5)0.249
AP (UI/L)79.61 (61, 100)66.2 (51.83, 94.44)0.13089.5 (78, 106)77 (68, 105.5)0.095
iPTH (pg/mL)266.5 (158.7, 481.85)336 (185.7, 798)0.179140 (94.35, 260.95)118.4 (87.5, 202.6)0.176
Creatinine (mg/dL)8.1 (6.8, 8.73)9.42 (7.7, 11.3)<0.0012.18 (1.6, 3.44)2.47 (1.8, 4.5)0.225
Albumin (g/dL)3.87 (3.62, 4)3.94 (3.74, 4.13)0.0533.79 (3.61, 4.07)3.76 (3.49, 4.26)0.875
eGFR (mL/min/m2) 23 (13.5, 32)26 (12, 38)0.354
Testosterone (ng/mL)0.7 (0.5, 1.3)3.65 (2.5, 4.8)<0.0010.5 (0.3, 0.6)3.3 (2.3, 4.3)<0.001
Leptin (ng/mL)24.3 (5.43, 49.47)3.49 (0.57, 9.58)<0.00135.5 (13.93, 54.97)3.82 (1.54, 7.68)<0.001
Betablockers n (%)21 (55.3)29 (58)0.79719 (63.3)20 (52.6)0.376
ACEI + ARB14 (36.8)23 (46)0.80415 (50)17 (44.7)0.666
Statin n (%)7 (18.4)9 (18)0.00210 (35.7)11 (29.7)0.609
Antiagregants n (%)17 (44.7)15 (30)0.1557 (24.1)12 (31.6)0.503
Ba PWV (cm/s) 10.6 (9.7, 12.2)10.65 (9.05, 11.95)0.516
NMD (%)9.68 (4.65, 14.09)4.34 (1.83, 11.69)0.014
FMD (%)11.11 (4.55, 15.38)8.16 (4.08, 14.29)0.454
HD duration69 (34, 88)54 (22, 83)0.034
Significant p value with bold; n—number of people; no.—number of cells; BMI—body mass index; SBP—systolic blood pressure; DBP—diastolic blood pressure; PP—pulse pressure; eGFR—estimated glomerular filtration rate; LTM—lean tissue mass; ATM—adipose tissue mass; LDL—low-density lipoprotein; HDL—high-density lipoprotein; iPTH—intact parathyroid hormone; Ba PWV—brachial–ankle pulse wave velocity; ACEI—angiotensin-converting enzyme inhibitors; ARB—angiotensin II receptor blockers; WC—waist circumference; NMD—nitroglycerin-mediated vasodilatation; FMD—flow-mediated vasodilation; hs-CRP—high-sensitive C-reactive protein; AP—alkaline phosphatase; WBC—white blood cell; HD—hemodialysis; arithmetic mean ± standard deviation; median (25th–75th percentile).
Table 3. Correlation and multivariate linear regression between the parameters and leptin in hemodialysis (HD) group A.
Table 3. Correlation and multivariate linear regression between the parameters and leptin in hemodialysis (HD) group A.
VariableWomen in Group A (n = 38)Men in Group A (n = 50)Group AMultivariate Analysis in Group A
Leptin (ng/mL)Correlation CoefficientpCorrelation CoefficientpCorrelation CoefficientpB Coefficient 95%CI (Lower, Upper)p
Age (years)0.1660.3200.1590.2690.2100.049
WC (cm)0.624<0.0010.620<0.0010.558<0.001
DBP (mmHg)−0.0480.773−0.1680.243−0.1840.086
Triglycerides (mg/dL)0.1520.3610.2010.1620.2350.028
LDL-cholesterol (mg/dL)0.0040.9830.2710.0570.2210.038
Total Cholesterol (mg/dL)−0.0560.7400.3670.0090.2700.011
iPTH (pg/mL)−0.1220.464−0.2360.098−0.2200.039
hs-CRP (mg/dL)0.1930.2460.3370.0170.2840.0070.35 (0.07, 0.63)0.016
WBC (no/mmc)0.1040.5340.4440.0010.2530.017
Testosterone (ng/mL)−0.1530.3590.2300.108−0.377<0.001−1.83 (−3.44, −0.23)0.026
BMI (kg/m2)0.713<0.0010.713<0.0010.737<0.001
LTM (kg)−0.2620.112−0.2710.065−0.439<0.001
ATM (kg)0.716<0.0010.787<0.0010.751<0.0010.86 (0.61, 1.12)<0.001
NMD (%)−0.3790.039−0.1370.392−0.1770.139
Significant p value with bold; n—number of people; BMI—body mass index; DBP—diastolic blood pressure; LTM—lean tissue mass; ATM—adipose tissue mass; LDL—low-density lipoprotein; iPTH—intact parathormone; WC—waist circumference; NMD—nitroglycerin-mediated vasodilatation; FMD—flow-mediated vasodilation; hs-CRP—high-sensitive C-reactive protein, WBC—white blood cell.
Table 4. Correlation between the parameters and testosterone in hemodialysis (HD) group A.
Table 4. Correlation between the parameters and testosterone in hemodialysis (HD) group A.
VariableWomen in Group A (n = 38)Men in Group A (n = 50)Group AMultivariate Analysis of Group A
Testosterone (ng/mL)Correlation CoefficientpCorrelation CoefficientpCorrelation CoefficientpCorrelation Coefficientp
Age (years)−0.1190.475−0.0800.580−0.2210.039
SBP (mmHg)−0.1500.3690.1850.1990.1790.095
DBP (mmHg)0.0760.6510.2120.1380.2980.005
Creatinine (mg/dL)0.0220.894−0.0790.5850.2690.011
LDL cholesterol (mg/dL)0.1030.539−0.1420.324−0.1820.090
Total cholesterol (mg/dL)0.1540.357−0.1700.238−0.2350.027
Phosphorus (mg/dL)0.2790.0900.1400.3310.2230.037
Ferritin (ng/mL)0.1490.371−0.2250.116−0.2360.027
Hemoglobin (g/dL)0.1740.2950.3300.0190.2560.0160.84 (0.38, 1.30)<0.001
Leptin (ng/mL)−0.1530.3590.2300.108−0.377<0.001
BMI (kg/m2)−0.0320.8500.2310.114−0.2000.064
LTM (kg)−0.1470.3780.1450.3320.510<0.0010.09 (0.03, 0.15)0.006
NMD (%)0.1990.291−0.3160.044−0.1450.226
Significant p value with bold; n—number of people; SBP—systolic blood pressure; DBP—diastolic blood pressure; LDL—low-density lipoprotein; BMI—body mass index; LTM—lean tissue mass; NMD—nitroglycerin-mediated vasodilatation.
Table 5. Correlation between the parameters and leptin in the pre-dialysis chronic kidney disease (CKD) patients (n = 73).
Table 5. Correlation between the parameters and leptin in the pre-dialysis chronic kidney disease (CKD) patients (n = 73).
VariableWomen in Group Pre-Dialysis
(n = 36)		Men in Group Pre-Dialysis (n = 38)Group Pre-DialysisMultivariate Analysis on Group Pre-Dialysis
Leptin (ng/mL)Correlation CoefficientpCorrelation CoefficientpCorrelation CoefficientpB Coefficient 95%CI (Lower, Upper)p
Testosterone (ng/mL)−0.2380.162−0.1130.499−0.570<0.001−6.09 (−8.87, −3.30)<0.001
DBP (mmHg)−0.1910.349−0.2050.253−0.2990.021-
Triglycerides (mg/dL)0.4260.0610.0650.7480.2540.084-
Calcium (mg/dL)0.2770.1190.1660.3270.3640.002-
Phosphorus (mg/dL)−0.1810.329−0.3170.064−0.0780.533
iPTH (pg/mL)−0.4250.027−0.1090.545−0.1730.185
Fasting glucose (mg/dL)0.5220.0090.2930.0830.3020.0190.16 (0.04, 0.03)0.013
Ferritin (ng/mL)−0.1690.453−0.3230.076−0.2940.033-
Bicarbonate level (mEq/L)0.3830.3080.5380.0210.4080.034-
BMI (kg/m2)0.709<0.0010.5050.0030.595<0.0014.56 (3.02, 6.10)<0.001
LTM (kg)0.0480.818−0.0940.628−0.3840.004−0.97 (−1.4, −0.54)<0.001
ATM (kg)0.685<0.0010.4460.0150.591<0.0010.81 (0.48, 1.15)<0.001
eGFR (mL/min/1.73 m2)0.4160.0120.3400.0370.2640.023-
Significant p value with bold; n—number of people; DBP—diastolic blood pressure; LDL—low-density lipoprotein; eGFR—estimated glomerular filtration rate; iPTH—intact parathyroid hormone; BMI—body mass index; LTM—lean tissue mass; ATM—adipose tissue mass.
Table 6. Correlation between the parameters and testosterone in pre-dialysis chronic kidney disease (CKD) patients.
Table 6. Correlation between the parameters and testosterone in pre-dialysis chronic kidney disease (CKD) patients.
VariableWomen in Group Pre-Dialysis (n = 36)Men in Group Pre-Dialysis (n = 38)Group Pre-DialysisMultivariate Analysis on Group Pre-Dialysis
Testosterone (ng/mL)Correlation CoefficientpCorrelation CoefficientpCorrelation CoefficientpB Coefficient 95%CI (Lower, Upper)p
Leptin (ng/mL)−0.2380.162−0.1130.499−0.570<0.001−0.03 (−0.05, −0.01)0.009
WC (cm)0.5730.0400.0270.9130.2330.200
SBP (mmHg)−0.2280.2620.1240.4910.2550.051
LDL-cholesterol (mg/dL)0.1540.5290.0860.6700.2640.076
Calcium (mg/dL)−0.1730.335−0.0560.743−0.2960.013
LTM (kg)0.2270.2750.0220.9110.4500.0010.05 (0.01, 0.09)0.029
eGFR (mL/min/1.73 m2)−0.3360.0450.0540.746−0.0650.585
Significant p value with bold; n—number of people; WC— waist circumference; SBP—sistolic blood pressure; LDL—low-density lipoprotein; eGFR—estimated glomerular filtration rate; LTM—lean tissue mass.
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

Share and Cite

MDPI and ACS Style

Rusu, C.C.; Kacso, I.; Moldovan, D.; Potra, A.; Tirinescu, D.; Ticala, M.; Orasan, R.; Budurea, C.; Anton, F.; Valea, A.; et al. Leptin Is Associated with Testosterone, Nutritional Markers, and Vascular Muscular Dysfunction in Chronic Kidney Disease. Int. J. Mol. Sci. 2024, 25, 7646. https://doi.org/10.3390/ijms25147646

AMA Style

Rusu CC, Kacso I, Moldovan D, Potra A, Tirinescu D, Ticala M, Orasan R, Budurea C, Anton F, Valea A, et al. Leptin Is Associated with Testosterone, Nutritional Markers, and Vascular Muscular Dysfunction in Chronic Kidney Disease. International Journal of Molecular Sciences. 2024; 25(14):7646. https://doi.org/10.3390/ijms25147646

Chicago/Turabian Style

Rusu, Crina Claudia, Ina Kacso, Diana Moldovan, Alina Potra, Dacian Tirinescu, Maria Ticala, Remus Orasan, Cristian Budurea, Florin Anton, Ana Valea, and et al. 2024. "Leptin Is Associated with Testosterone, Nutritional Markers, and Vascular Muscular Dysfunction in Chronic Kidney Disease" International Journal of Molecular Sciences 25, no. 14: 7646. https://doi.org/10.3390/ijms25147646

APA Style

Rusu, C. C., Kacso, I., Moldovan, D., Potra, A., Tirinescu, D., Ticala, M., Orasan, R., Budurea, C., Anton, F., Valea, A., Bondor, C. I., & Carsote, M. (2024). Leptin Is Associated with Testosterone, Nutritional Markers, and Vascular Muscular Dysfunction in Chronic Kidney Disease. International Journal of Molecular Sciences, 25(14), 7646. https://doi.org/10.3390/ijms25147646

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop